J Shanghai Jiaotong Univ Sci ›› 2023, Vol. 28 ›› Issue (4): 432-.doi: 10.1007/s12204-022-2440-7

• Medicine-Engineering Interdisciplinary Research • Previous Articles    

Gene Expression Profiling Identifies Potential Biomarkers for Colorectal Cancer Using NanoString nCounter Assay

使用NanoString nCounter测定结直肠癌的潜在生物标志物

ZHAO Hui (赵晖),WEN Baiqing (文柏清),KANG Yani*(康亚妮)   

  1. (Bio-ID Center, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China)
  2. (上海交通大学 生物医学工程学院 Bio-ID中心,上海200240)
  • Received:2021-08-26 Accepted:2021-10-18 Online:2023-07-28 Published:2023-07-31

Abstract: Colorectal cancer (CRC) is one of the most common malignancies worldwide. Development of predictivemolecular markers may help to achieve the best outcome in clinic. The purpose of this study is to identify thedifferentially expressed genes and new potential predictive and prognostic molecular biomarkers for CRC. Inthis study, CRC and matched normal tissues acquired from the same patient were used to extract total RNA.The NanoString nCounter assay was applied to determine the differentially expressed genes. The results werethen validated by using the Cancer Genome Atlas data. Finally, we identified 27 genes that revealed significantcorrelation with CRC in the tumor tissue. Several genes in the pan-cancer panel showed significant differentialexpression, which were more universal than others in the CRC tissue. Since some of them have not been reportedas being directly related to CRC yet, future mechanism studies can be designed based on this study. Our studydemonstrated NanoString nCounter assay could serve as an alternative approach for gene expression analysis andidentified several unreported differently expressed genes in CRC patients, which may provide some importantclues for more in-depth study of CRC and serve as potential predictive molecular biomarkers for clinical diagnosisapplication.

Key words: colorectal cancer, biomarkers, gene expression, NanoString nCounter assay

摘要: 大肠癌(CRC)是世界上最常见的恶性肿瘤之一。预测性分子标记物的开发可能有助于在临床上获得最佳结果。本研究的目的是鉴定CRC的差异表达基因和新的潜在预测和预后分子生物标志物。在这项研究中,使用从同一患者获得的CRC和匹配的正常组织来提取总RNA。应用NanoString nCounter测定法测定差异表达的基因。然后使用癌症基因组图谱数据验证结果。最后,我们在肿瘤组织中鉴定了27个与CRC显著相关的基因。泛癌组中的几个基因显示出显著的差异表达,这在CRC组织中比其他基因更普遍。由于其中一些尚未被报道与CRC直接相关,因此可以根据这项研究设计未来的机制研究。我们的研究表明,NanoString nCounter检测可以作为基因表达分析的替代方法,并在CRC患者中鉴定了几个未报告的不同表达基因,这可能为更深入地研究CRC提供一些重要线索,并作为临床诊断应用的潜在预测分子生物标志物。

关键词: 大肠癌,生物标志物,基因表达,NanoString nCounter assay

CLC Number: